» Articles » PMID: 33549872

Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study

Overview
Specialty Gastroenterology
Date 2021 Feb 7
PMID 33549872
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Efforts to assess and improve the effectiveness of Barrett's esophagus (BE) screening and surveillance are ongoing in the United States. Currently, there are limited population-based data in the United States to guide these efforts.

Methods: We performed a retrospective cohort study using data from large commercial and Medicare Advantage health plans in the United States from 2004 - 2019. We identified individuals with BE and analyzed the proportion who developed EAC. EACs were classified as prevalent EAC (diagnosed within 30 days of index endoscopy), post-endoscopy esophageal adenocarcinoma (PEEC, diagnosed 30 - 365 days after index endoscopy), and incident EAC (diagnosed 365 days or more after index endoscopy). Using this cohort, we performed a nested case-control study to identify factors associated with prevalent EAC at BE diagnosis and study healthcare utilization prior to BE diagnosis.

Results: We identified 50,817 individuals with incident BE. Of the 366 who developed EAC, 67.2%, 13.7%, and 19.1% were diagnosed with prevalent EAC, PEEC, and incident EAC respectively. Factors positively associated with prevalent EAC versus BE without prevalent EAC included male sex, dysphagia, weight loss, and Charlson-Deyo comorbidity score. In those with prevalent EAC, most patients with dysphagia or weight loss had their symptoms first recorded within three months of EAC diagnosis. Healthcare utilization rates were similar between those with and without prevalent EAC.

Conclusions: Two-thirds of EACs among individuals with BE are diagnosed at the time of BE diagnosis. Additionally, PEEC accounts for 14% of these EACs. These results may guide future research studies that investigate novel BE diagnostic strategies that reduce the morbidity and mortality of EAC.

Citing Articles

Clinical application of capsule sponge testing in symptomatic reflux disease: a national prospective cohort study.

Chien S, Glen P, Bryce G, Cruickshank N, Penman I, Robertson K BMC Gastroenterol. 2024; 24(1):431.

PMID: 39592951 PMC: 11590222. DOI: 10.1186/s12876-024-03503-5.


Prospect and Challenges of Volatile Organic Compound Breath Testing in Non-Cancer Gastrointestinal Disorders.

Zheng W, Pang K, Min Y, Wu D Biomedicines. 2024; 12(8).

PMID: 39200279 PMC: 11351786. DOI: 10.3390/biomedicines12081815.


The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.

Choi Y, Bedford A, Pollack S Cancers (Basel). 2024; 16(13).

PMID: 39001449 PMC: 11240336. DOI: 10.3390/cancers16132386.


Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation.

Chien S, Glen P, Penman I, Cruickshank N, Bryce G, Crumley A Br J Surg. 2024; 111(5).

PMID: 38736137 PMC: 11089076. DOI: 10.1093/bjs/znae117.


Adherence to quality indicators and best practices in surveillance endoscopy of Barrett's esophagus: A video-based assessment.

Enke T, Keswani R, Triggs J, Gannavarapu B, Mittal C, Sinha J Endosc Int Open. 2024; 12(1):E90-E96.

PMID: 38250164 PMC: 10798847. DOI: 10.1055/a-2226-3689.


References
1.
Visrodia K, Iyer P, Schleck C, Zinsmeister A, Katzka D . Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study. Dig Dis Sci. 2015; 61(1):158-67. PMC: 4639465. DOI: 10.1007/s10620-015-3697-6. View

2.
Kapoor N, Bassi A, Sturgess R, Bodger K . Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut. 2004; 54(1):40-5. PMC: 1774389. DOI: 10.1136/gut.2004.039438. View

3.
Vajravelu R, Mamtani R, Scott F, Waxman A, Lewis J . Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. Gastroenterology. 2018; 155(5):1416-1427. PMC: 6219900. DOI: 10.1053/j.gastro.2018.07.026. View

4.
Thrift A . Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?. Dig Dis Sci. 2018; 63(8):1988-1996. DOI: 10.1007/s10620-018-5068-6. View

5.
Kolb J, Han S, Scott F, Murphy C, Hosokawa P, Wani S . Early-Onset Esophageal Adenocarcinoma Presents With Advanced-Stage Disease But Has Improved Survival Compared With Older Individuals. Gastroenterology. 2020; 159(6):2238-2240.e4. PMC: 9440641. DOI: 10.1053/j.gastro.2020.08.002. View